AstraZeneca lines up finance chief Dunoyer to head Alexion By Reuters

© Reuters. FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble

(Reuters) – AstraZeneca (NASDAQ:) said on Friday it had appointed Alexion (NASDAQ:)’s Aradhana Sarin as its new chief financial officer as it shifts existing CFO Marc Dunoyer to a new role leading the U.S.-based drugmaker after the pair’s merger.

AstraZeneca agreed to buy Alexion in December in its largest ever deal, a bet on rare-disease immunology which also includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.

London-listed AstraZeneca said Sarin’s appointment was conditional upon the completion of its $39 billion buyout of Alexion.

Dunoyer will become the U.S. drugmaker’s chief executive officer while also being appointed chief strategy officer at AstraZeneca. He will leave the Anglo-Swedish company’s board but continue to report to CEO Pascal Soriot.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*